Therapeutic Effect of Meglumine Cyclic Adenosine Monophosphate on Chronic Heart Failure in Patients with Type 2 Diabetes Mellitus and Coronary Heart Disease
Abstract：Objective:To observe the clinical effect and safety of meglumine cyclic adenosine monophosphate (MCA) in treating chronic heart failure (CHF) in patients with type 2 diabetes mellitus and coronary heart disease.Method:60 cases diagnosed with CHF in patients with type 2 diabetes mellitus and coronary heart disease were treated in author’s hospital,were randomlydⅣided into a control group and treatment group,30 cases in each. The control group was treated with conventional basic therapy,the treatment group was treated with MCA by intravenous infusion about 180 mg once a day based on the basic therapy. The therapeutic period was 2 weeks. After the end of treatment 4 weeks the NYHA stating,left ventricular ejection fraction(LVEF),the concentration of plasma amino terminal brain natriuretic peptide precursor (NT-proBNP) were compared with in the same group and between the two groups before and after treatment. Result:There was no significant difference in the observed indicators between the two groups before therapy(P>0. 05),in both groups after treatment heart function and LVEF increasd significantly and plasma NT-proBNP concentration decreased significantly,the difference was statistically significant(P<0.01),but the patients in the treatment group had a better clinical effect and a improved heart function than the control group,the difference was statistically significant(P<0.05). Conclusion:Good therapeutic effect was achieved in the group with comnbined treatment without obvious side effect.
Keywords：Chronic heart failureType 2 diabetes mellitusCoronary heart diseaseMeglumine cyclic adenosine monophosphate
Publication Date：2014-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：3( 9-10,11 )